Global Partners LP (GLP)
$
47.22
-0.62 (-1.31%)
Key metrics
Financial statements
Free cash flow per share
-1.8832
Market cap
1.6 Billion
Price to sales ratio
0.0857
Debt to equity
3.0148
Current ratio
1.2144
Income quality
2.8535
Average inventory
487.1 Million
ROE
0.1261
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Global Partners LP is actively engaged in the purchasing, selling, gathering, blending, storing, and logistical transportation of a variety of petroleum products including gasoline, gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane, catering to wholesalers, retailers, and commercial clients throughout the New England states, Mid-Atlantic region, and New York. The company operates a comprehensive Wholesale segment that supplies home heating oil, branded and unbranded gasoline, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. Additionally, it aggregates crude oil via truck or pipeline across the mid-continent region of the United States and Canada, utilizing rail and barge transport to deliver to refiners. Its Gasoline Distribution and Station Operations segment services gasoline station operators and sub-jobbers with both branded and unbranded gasoline while managing networks of gasoline stations and convenience stores that offer car wash, lottery, and ATM services. Within its Commercial segment, the company provides unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to public sector entities, commercial clients, and industrial users, alongside custom blended fuels. As of December 31, 2021, Global Partners LP held a diverse portfolio consisting of 1,595 owned, leased, and supplied gasoline stations, of which 295 included directly operated convenience stores, and maintained 26 bulk terminals with a total storage capacity of 11.9 million barrels. The EBITDA is $389,394,000.00 a key indicator of the company's operational profitability, and the EBITDA ratio is 0.02 highlighting the company's operational efficiency. The operating expenses amount to $806,673,000.00 encompassing various operational costs incurred, while the weighted average number of diluted shares outstanding is 34,339,000.00 reflecting potential dilution effects. Furthermore, the weighted average number of shares outstanding is 33,840,000.00 highlighting the company's shareholder base. In terms of market positioning, the stock is affordable at $49.24 making it suitable for budget-conscious investors. However, it has a low average trading volume of 50,470.00 indicating lower market activity. With a market capitalization of $1,597,256,118.00 the company is classified as a small-cap player, which is significant in its respective field. It is a key player in the Oil & Gas Midstream industry, contributing significantly to the overall market landscape, and it belongs to the Energy sector, driving innovation and growth. This dynamic positioning within the market underscores the company's potential for future development and influence.
Is Global Partners LP (GLP) a good investment?
Investing in Global Partners LP (GLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Global Partners LP (GLP)'s stock forecast?
Analysts predict Global Partners LP stock to fluctuate between $39.58 (low) and $60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Global Partners LP's market capitalization?
As of 2026-01-30, Global Partners LP's market cap is $1,597,256,118, based on 33,825,839 outstanding shares.
How does Global Partners LP compare to competitors like Exxon Mobil Corporation?
Compared to Exxon Mobil Corporation, Global Partners LP has a Lower Market-Cap, indicating a difference in performance.
Does Global Partners LP pay dividends?
Global Partners LP pays dividends. The current dividend yield is 7.35%, with a payout of $0.76 per share.
How can I buy Global Partners LP (GLP) stock?
To buy Global Partners LP (GLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GLP. Place an order (Market, Limit, etc.).
What is the best time to invest in Global Partners LP?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Global Partners LP perform in the last earnings report?
Revenue: $17,163,566,000 | EPS: $2.45 | Growth: -35.01%.
Where can I find Global Partners LP's investor relations reports?
Visit https://www.globalp.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Global Partners LP?
You can explore historical data from here
What is the all-time high and low for Global Partners LP stock?
All-time high: $60 (2025-02-21) | All-time low: $19.45 (2021-08-19).
What are the key trends affecting Global Partners LP stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison.
marketwatch.com
Citrini Research founder James Van Geelen identifies potential big money trends and stakes his claim far ahead of the crowd.
globenewswire.com
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss
businesswire.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estim.
seekingalpha.com
Cal-Maine Foods earns a reiterated buy rating, driven by rapid expansion into prepared foods and a strong, debt-free balance sheet. Prepared food sales surged 586.4% in Q2'FY26, backed by significant acquisitions in recent years, enhancing margin stability and business diversification going forward. CALM's >$1.1 billion cash position and zero debt provide exceptional downside protection and strategic flexibility amid ongoing macroeconomic pressures.
benzinga.com
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge.
prnewswire.com
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.
accessnewswire.com
VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model.
cnbc.com
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the company has the potential to deliver up to 10 new products by the end of the decade.
fool.com
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug.
See all news
